Real News
Real News
Global News

Cellular Intelligence strikes deal with Novo Nordisk to advance Parkinson’s cell therapy

newslab
In this photo illustration, a smartphone displays the logo of Novo Nordisk (NYSE: NVO), a Denmark-based pharmaceutical company specializing in diabetes care, obesity treatment, in front of a screen showing the company
‘This cell therapy Parkinson’s program is truly innovative and exemplifies the powerful convergence of exciting academic discovery with the uncompromising quality of a global pharmaceutical leader.’